Introduction {#Sec1}
============

Hepatitis B and C virus infections are responsible for more than 300 million chronically infected individuals worldwide \[[@CR1], [@CR2]\]. Brazil is the largest country in Latin America, where more than 500,000 cases of hepatitis B or C were reported to the Brazilian Health Ministry from 1999 to 2017 \[[@CR3]\]. However, the real prevalence of these infections is likely higher, as the country occupies an extensive 8.5 million km^2^ area, including many remote regions which suffer from little to no healthcare access.

Hepatitis B and C diagnosis is made by detecting antigens, antibodies or viral genome from serum samples obtained through venous blood collection \[[@CR4]\]; however, trained personnel and infrastructure to collect blood are required. Furthermore, low temperature storage conditions and transportation are necessary, which may be difficult to obtain in limited-resource settings. According to WHO guidelines, DBS could be a useful tool to obtain blood samples for diagnosis in vulnerable populations or remote areas \[[@CR5]\]. Some studies have reported detection of HBV and HCV markers using manual enzyme immunoassays \[[@CR6]--[@CR11]\], but little is known about the utility of the electrochemiluminescence immunoassay "ECLIA" for anti-HCV, HBsAg and anti-HBc detection from DBS samples. This method is fast, employs a small amount of sample, is highly accurate and can yield results in few minutes.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

This cross-sectional study included 1385 paired plasma and DBS samples (71 HBsAg positive, 185 anti-HBc positive, 108 anti-HCV positive, 298 HBsAg negative, 357 anti-HBc negative, 366 anti-HCV negative) collected at the Viral Hepatitis Clinic (FIOCRUZ, RIO DE JANEIRO, BRAZIL). This study was approved by the Fiocruz Ethics Committee. Informed written consent was obtained from each individual.

The samples were obtained from referred patients and suspected cases received at the clinic to determine hepatitis diagnosis. Paired serum and DBS samples were obtained, where 6 mL whole blood was collected from each patient and 75 µL was spotted on a Whatman 903 protein saver card (Whatman, GE Healthcare, NJ), until 12-mm pre-printed circular paper disks were completely filled. To elute DBS samples, a 12-mm disc of filter paper was cut and transferred to a microtube containing 500 µL of PBS/BSA 0.5% for 18 to 24 h.

After incubation, eluate was directly submitted to the following ECLIA: Elecsys anti-HCV II, Elecsys HBsAg II and Elecsys anti-HBc II (Roche Diagnostics) following the manufacturer's instructions. In the Anti-HCV and HBsAg assay, samples with sample/cutoff (S/CO) values \< 1.0 are considered non-reactive while for anti-HBc assay, non-reactive samples should present S/CO \> 1.0.

Descriptive statistics comprise the mean ± the standard deviation, with a preliminary assessment using contingency tables and respective statistics. The results obtained with serum were used as a reference to assess sensitivity, specificity, positive predictive value, negative predictive value and respective confidence interval (CI).

Concordance between the results obtained for the paired DBS and sera samples was assessed using the Kappa index (k). According to international standards, findings should be interpreted as follows: \< 0.20 corresponds to poor agreement; 0.21--0.40 fair agreement; 0.41--0.60 moderate agreement; 0.61--0.80 good agreement, and 0.81--1.00 corresponds to very good agreement \[[@CR12]\]. Analyses were performed using GraphPad InStat 3.01 (GraphPad Software, San Diego, CA).

Results {#Sec4}
-------

Anti-HCV was detected in 103 DBS samples from 108 paired, positive serum specimens and undetected in 364 DBS samples from 366 paired, negative serum specimens, giving a sensitivity and specificity of 95.4% and 99.4% respectively. HBsAg was detected in 67 DBS samples out of 71 positive, paired serum specimens and was undetected among 295 DBS samples from 298 paired, negative serum specimens, giving a sensitivity and specificity of 94.4% and 99%, respectively. Anti-HBc was detected in 160 DBS samples from 185 paired, positive serum specimens and undetected in 349 DBS samples from 357 paired, negative serum specimens, giving a sensitivity and specificity of 86.5% and 97.8% respectively. Overall, the Kappa index indicated a high agreement between results obtained for the serum and DBS samples (k: 0.95, 0.93 and 0.86 for anti-HCV, HBsAg, anti-HBc, respectively) (Table [1](#Tab1){ref-type="table"}).Table 1Sensitivity, specificity, negative and positive predictive values and kappa index for anti-HCV, HBsAg and anti-HBs detection in DBS samples using ECLIAAnti-HCVAnti-HBcHBsAgValue (%)IC (%)Value (%)IC (%)Value (%)IC (%)Sensitivity95.3789.53--98.4886.4980.70--91.0694.3786.20--98.44Specificity99.4598.04--99.9397.7695.63--99.0398.9997.09--99.79Positive predictive value98.1092.82--99.5295.2490.96--97.5595.7187.85--98.57Negative predictive value98.6496.87--99.4293.3290.65--95.2698.6696.61--99.48Kappa index0.9570.926--0.9880.8610.815- 0.9070.9380.893--0.983

Discussion {#Sec5}
----------

In this study, we evaluated the utility of automated ECLIA for HBsAg, anti-HBc, and anti-HCV detection in DBS samples. High sensitivity and specificity were found for anti-HCV detection comparable to previous study of Marques et al. that used manual EIA for anti-HCV detection (97.5% sensitivity and 99% specificity for RADIM EIA), by McCarron et al. \[[@CR13]\] who used EIA Monolisa anti-HCV (100% sensitivity and 87.5% specificity), and Tuaillon et al. \[[@CR14]\] who employed an Ortho HCV 3.0 enzyme-linked immunosorbent assay kit on DBS (99% sensitivity and specificity). These results demonstrated the utility of ECLIA in the detection of anti-HCV in DBS as equivalent to that of the enzyme immunoassay, which could increase the access of diagnosis.

Regarding HBsAg detection in DBS using ECLIA, we found high sensitivity (94.37%) and specificity (98.99%) compared to serum results. The same was found by Mossner et al. \[[@CR15]\] using the Architect system (Abbott Diagnostics, Delkenheim, Germany) where HBsAg sensitivity was 96.5% and specificity was 99%. Other studies also found sensitivities and specificities above 99% using the chemiluminescent microparticle immunoassay \[[@CR16]--[@CR18]\].

The present study also evaluated anti-HBc marker detection in DBS, which is useful in identifying previous exposure to HBV. In the present study, high specificity (97.76%) was observed and sensitivity of anti-HBc detection was 86.49%, which is similar to the observations of Ross et al. \[[@CR17]\] (86.3%) and higher than previously reported by Mossner et al. \[[@CR15]\] using the Architect system (Abbott Diagnostics) (68%). The low sensitivity of anti-HBc detection in DBS could be attributable to the presence of other infections, such as HIV. Ross et al. \[[@CR17]\] observed high sensitivity of anti-HBc detection when HIV-infected individuals were excluded from the analysis (97.1%). However, data regarding HIV status was not available in the present study.

To our knowledge, this is the first report of the analytical performance characteristics of testing HBsAg, anti-HBc and anti-HCV in DBS eluates with the ROCHE ECLIA system. DBS specimens could be a reliable alternative testing specimen, which may increase hepatitis B and C diagnostic opportunities for rural, remote and hard to reach regions. DBS could be easily collected and transported to reference laboratories for testing using automated assays.

Limitations {#Sec6}
===========

Lack of clinical data and risk factors of the population studied that could explain false negative or positive results.Information regarding HIV or high-risk status, such as intravenous drug use, which could improve analysis of the methodological efficiency.
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